Grant Pickering Sells 2,616 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVXGet Free Report) CEO Grant Pickering sold 2,616 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $73.91, for a total transaction of $193,348.56. Following the transaction, the chief executive officer now owns 149,978 shares of the company’s stock, valued at approximately $11,084,873.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Grant Pickering also recently made the following trade(s):

  • On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total transaction of $1,980,900.00.
  • On Tuesday, January 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $63.92, for a total transaction of $958,800.00.
  • On Tuesday, January 2nd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $63.89, for a total transaction of $167,136.24.
  • On Tuesday, December 26th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $61.70, for a total transaction of $925,500.00.
  • On Friday, November 24th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $49.09, for a total transaction of $736,350.00.

Vaxcyte Price Performance

Vaxcyte stock opened at $74.83 on Wednesday. Vaxcyte, Inc. has a 12-month low of $34.11 and a 12-month high of $76.72. The stock has a market capitalization of $7.12 billion, a P/E ratio of -22.40 and a beta of 0.93. The firm’s 50-day moving average is $61.84 and its two-hundred day moving average is $53.69.

Vaxcyte (NASDAQ:PCVXGet Free Report) last released its quarterly earnings results on Monday, November 6th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.07). As a group, analysts forecast that Vaxcyte, Inc. will post -3.22 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently modified their holdings of the company. Xponance Inc. boosted its stake in shares of Vaxcyte by 3.0% during the 4th quarter. Xponance Inc. now owns 5,672 shares of the company’s stock worth $356,000 after purchasing an additional 163 shares during the last quarter. Ellsworth Advisors LLC boosted its position in shares of Vaxcyte by 2.6% in the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock worth $506,000 after acquiring an additional 207 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Vaxcyte by 0.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock worth $3,211,000 after acquiring an additional 296 shares during the last quarter. Strs Ohio boosted its position in shares of Vaxcyte by 3.9% in the fourth quarter. Strs Ohio now owns 10,700 shares of the company’s stock worth $671,000 after acquiring an additional 400 shares during the last quarter. Finally, Alps Advisors Inc. boosted its position in shares of Vaxcyte by 0.6% in the third quarter. Alps Advisors Inc. now owns 69,305 shares of the company’s stock worth $3,533,000 after acquiring an additional 426 shares during the last quarter.

Wall Street Analysts Forecast Growth

PCVX has been the subject of a number of analyst reports. Mizuho initiated coverage on shares of Vaxcyte in a research report on Thursday, December 7th. They set a “buy” rating and a $69.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $58.00 price objective on shares of Vaxcyte in a research report on Tuesday, November 7th. Bank of America increased their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $68.40.

View Our Latest Stock Analysis on PCVX

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Read More

Insider Buying and Selling by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.